Undifferentiated Pleomorphic Sarcoma
Synonyms: UPS, Malignant Fibrous histiocytoma (historical), MFH
Diagnosis of exclusion - must rule out specific sarcoma subtypes
Quick Facts
Behaviour
Malignant
Category
Soft tissue
Grade
High
Synonyms
- UPS
- Malignant Fibrous histiocytoma (historical)
- MFH
Category
Soft tissue
Behaviour
Malignant
Grade
High
Gender
Male
Tissue of Origin
No identifiable cell line
Epidemiology
- One of the most common soft tissue sarcomas in adults
- Peak incidence 50-70 years
- Can be radiation-associated
Clinical Features
- Rapidly enlarging deep soft tissue mass
- Often >5cm at presentation
- Pain in 50%
- May present with metastatic disease (lung most common)
Location
- Lower extremity (especially thigh)
- Upper extremity
- Retroperitoneum
- Trunk
Imaging
- MRI: heterogeneous solid mass with areas of necrosis/haemorrhage
- Enhancement is heterogeneous
- Often deep to fascia
- CT chest for staging
Pathology
- Diagnosis of exclusion - High-grade pleomorphic sarcoma NOS
- No identifiable line of differentiation
- Marked pleomorphism, atypical mitoses
- Must exclude dedifferentiated liposarcoma (MDM2-), leiomyosarcoma, etc.
Genetics
- Complex karyotype, no specific recurrent translocation
- Must exclude MDM2 amplification (dedifferentiated liposarcoma)
Treatment
- Wide surgical excision with adequate margins
- Neoadjuvant/adjuvant radiotherapy for High-grade, deep, >5cm tumours
- Consider adjuvant chemotherapy (doxorubicin-based) for High-risk tumours
- Multidisciplinary sarcoma team management essential
Prognosis
- 5-year survival 50-65%
- Size >5cm, deep location, High grade = adverse factors
- Metastasis rate 30-40% (predominantly lung)
- Local recurrence 20-30%
Key Points
- Diagnosis of exclusion - must rule out specific sarcoma subtypes
- Previously called Malignant Fibrous histiocytoma (MFH)
- Always exclude MDM2 amplification to rule out dedifferentiated liposarcoma
- Managed with wide excision ± radiotherapy ± chemotherapy
Workup - Blood Tests
- FBC, U&E, LFTs, Bone profile (if Bone) - baseline and pre-chemotherapy
- LDH - elevated in advanced disease
Workup - Local Imaging
MRI primary site with gadolinium
Workup - Biopsy
- Core needle biopsy at sarcoma centre - en bloc excision of tract
- Histology: High-grade pleomorphic spindle cell sarcoma
- Comprehensive IHC + molecular: exclude other pleomorphic sarcomas (DDLPS with MDM2 amplification, etc.)
- Grade assignment essential
Workup - Staging
- CT chest/abdomen/pelvis - pulmonary and visceral metastases
- PET-CT - for systemic staging
Follow-up Summary
- 1
Years 1–2
3–4 monthly clinical review + CXR; MRI primary site at 3 months post-op then 6-monthly
- 2
CT chest every 3–4 months for first 2 years (pulmonary metastasis is primary concern)
- 3
Years 3–5
6-monthly clinical review + CXR; CT chest 6-monthly
- 4
Years 6–10
Annual clinical review + CXR; CT chest annually
- 5
Discharge at 10 years with documented self-monitoring advice
- 6
Radiotherapy patients
monitor irradiated field for late effects at each review
Medical disclaimer
The content on Sarcopedia is for educational and informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical diagnosis or treatment. Always consult with a qualified physician regarding any health concerns or before starting any new treatment. Reliance on any information provided on this site is solely at your own risk.